VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PROF
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
PROFProfound Medical Corp.
$6.50$197M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksPROFBalance Sheet

Profound Medical Corp. (PROF) Balance Sheet

12Y historyFree accessUpdated daily

The company maintains a conservative capital structure with a low debt-to-equity ratio of 0.13 as of 2026Q1, though this is offset by a substantial accumulated deficit of $295.8 million.

PROF Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14
Total Current Assets69.76M104.21M69.06M41.9M62.02M77.02M97.74M22.84M27.84M14M16.72M15.08M1.47M
Cash & Short-Term Investments50.46M81.8M54.91M26.21M46.52M67.06M83.91M14.82M22.53M8.83M15.5M14.79M1.47M
Cash Only50.46M81.8M54.91M26.21M46.52M67.06M83.91M14.82M22.53M8.83M15.5M7.58M1.47M
Short-Term Investments000000000007.21M0
Accounts Receivable9.45M9.86M7.04M7.29M6.34M1.41M7.43M3.31M1.52M3.57M5.7M00
Days Sales Outstanding157.66223.59252.91369.51346.5974.88371.35289.84289.58334.27---
Inventory9.03M11.28M5.8M6.99M7.94M7.4M5.33M3.67M2.67M1.14M310.11K00
Days Inventory Outstanding622.85875.3610.53905.57791.93689.13508.05751.72745.31172.27605.27--
Other Current Assets813.67K1.27M0001.15M1.07M1.03M224.87K458.07K518.49K100.39K148.42K
Total Non-Current Assets3.94M88.73M1.17M2.06M2.4M9.64M6.86M7.27M6.34M8.17M904.48K188.52K213.63K
Property, Plant & Equipment3.59M225K821.01K1.57M1.72M1.9M2.28M2.22M886.44K1.37M709.05K165.1K178.63K
Fixed Asset Turnover15.07x71.55x12.38x4.59x3.89x3.61x3.20x1.88x2.16x2.84x---
Goodwill000002.69M2.68M2.63M2.5M2.71M000
Intangible Assets129.42K138K261K490K680K1.43M1.9M2.41M2.95M4.09M195.44K23.42K35K
Long-Term Investments561.38K410.89K0003.62M0000000
Other Non-Current Assets087.96M0000000000-213.63K
Total Assets73.7M192.94M70.23M43.96M64.42M86.66M104.6M30.11M34.18M22.17M17.63M15.27M1.47M
Asset Turnover0.21x0.08x0.14x0.16x0.10x0.08x0.07x0.14x0.06x0.18x---
Asset Growth %168.52%174.71%59.78%-31.77%-25.66%-17.15%247.42%-11.91%54.15%25.77%15.44%938.08%-
Total Current Liabilities10.64M8.32M6.57M6.37M4.18M4.15M4.81M8.24M5.79M8.53M3.68M913.01K102.73K
Accounts Payable2.15M2.14M1.32M865K2.03M3.18M3.38M3.03M2.87M4.04M1.32M09.18K
Days Payables Outstanding100.25166.07138.61112.08202.74295.62322.31620.55802.93611.712.58K--
Short-Term Debt4.59M291.73K1.74M2.1M523K249.66K312K4.17M983.52K3.74M2.14M206.6K830.05K
Deferred Revenue (Current)2.2M0419K721K471K476.35K358K504.93K229.48K191.9K192.91K00
Other Current Liabilities1.69M5.83M1.03M1.42M621K247.66K744K521.75K1.48M586.19K29.28K706.41K-830.05K
Current Ratio6.56x12.52x10.52x6.58x14.82x18.56x20.32x2.77x4.81x1.64x4.54x16.52x14.32x
Quick Ratio5.71x11.17x9.64x5.48x12.92x16.78x19.22x2.33x4.35x1.51x4.46x16.52x14.32x
Cash Conversion Cycle680.27932.83724.831.16K935.77468.39557.09421.01231.96-105.16---
Total Non-Current Liabilities3.44M93.63M3.25M6.36M8.23M2M2.44M7.48M8.84M2.4M2.91M4.29M2.68M
Long-Term Debt06.16M2.92M5M6.65M005.18M10.62M352.98K3.87M5.56M1.95M
Capital Lease Obligations2.97M0203K504K817K1.13M1.36M1.64M-2.82M0000
Deferred Tax Liabilities86.83M86.83M059K0000250.64K-284.95K000
Other Non-Current Liabilities92.3K108.2K71K73K00014.65K-2.3M2.04M-961.24K-1.27M-1.95M
Total Liabilities14.08M101.95M9.81M12.73M12.42M6.15M7.25M15.71M14.63M10.93M6.59M5.21M102.73K
Total Debt7.49M6.45M5.12M7.87M8.23M1.38M1.68M10.99M8.78M4.09M4.94M4.21M2.78M
Net Debt-42.97M-75.34M-49.79M-18.35M-38.29M-65.69M-82.24M-3.84M-13.75M-4.74M-10.56M-3.37M1.31M
Debt / Equity0.13x0.07x0.08x0.25x0.16x0.02x0.02x0.76x0.45x0.36x0.45x0.42x2.03x
Debt / EBITDA-0.20x------------
Net Debt / EBITDA1.15x------------
Interest Coverage----36.27x-168.80x-459.67x-38.74x-13.52x-18.96x-12.91x-25.57x-2.88x-44.74x
Total Equity59.62M90.99M60.42M31.22M52M80.51M97.35M14.39M19.55M11.25M11.04M10.06M1.37M
Equity Growth %44.57%50.59%93.51%-39.96%-35.41%-17.3%576.36%-26.37%73.84%1.88%9.7%635.46%-
Book Value per Share1.643.012.441.472.503.935.631.301.951.832.664.256.31
Total Shareholders' Equity59.62M90.99M60.42M31.22M52M80.51M97.35M14.39M19.55M11.25M11.04M10.06M1.37M
Common Stock325.23M443.54M281.55M222.21M205.82M219.28M211.53M100.46M88.79M78.22M61.95M48.34M1.54M
Retained Earnings-295.76M-394.1M-245.17M-217.35M-189.36M-160.48M-129.99M-101.07M-81.52M-71.79M-53.16M-39.72M-453.15K
Treasury Stock000000000-4.85M000
Accumulated OCI4.03M6.88M2.74M5.57M16.84M4.74M4.57M-90.37K-21.07K-46.07K8.42K00
Minority Interest0000000000000

Key Metrics

Growth RegimeExpanding
ProfitabilityNegative
Balance SheetHealthy
Cash FlowBurning
Top Statement Risk

Persistent operational cash burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Capital Base Fluctuates With Growth

According to recent financial filings, PROF's total assets have exhibited significant volatility, peaking at $192.9M in 2025Q4 before contracting to $73.7M in 2026Q1, a trend that reflects the company's reliance on periodic capital raises to fund its ongoing commercial expansion and clinical development efforts.

The sharp contraction in total assets suggests that the company is actively consuming its capital base to support operations rather than building long-term asset value. Investors should monitor whether this volatility stabilizes as the company moves toward a more predictable revenue model.

Strong Cash Buffer Supports Runway

As reported in financial statements, PROF maintains a robust liquidity position with $50.5M in cash as of 2026Q1, providing a substantial buffer against its current operating losses and ensuring the company retains sufficient runway to continue its commercialization strategy without immediate reliance on external financing.

The current ratio of 6.56 indicates a high level of short-term solvency, which is critical for a company in the early-commercial stage. This liquidity profile suggests management is prioritizing operational flexibility over aggressive balance sheet optimization at this stage of the business cycle.

Minimal Leverage Preserves Financial Flexibility

Based on PROF's reported figures, the company maintains a conservative capital structure with debt levels remaining low, as evidenced by a debt-to-equity ratio of 0.13 in 2026Q1, which indicates that the firm is not currently burdened by significant interest obligations or restrictive debt covenants.

The minimal reliance on debt appears to be a strategic choice, allowing the company to avoid the risks associated with high leverage during a period of negative operating margins. This lack of debt provides a clean balance sheet that could facilitate future financing if necessary.

Accumulated Deficits Weigh On Equity

As indicated by historical balance sheet data, PROF's equity base is significantly impacted by a persistent and growing accumulated deficit, which reached -$295.8M in 2026Q1, highlighting the substantial historical investment required to bring the TULSA-PRO system to its current commercial stage.

The erosion of retained earnings underscores the high cost of market entry and the long-term nature of the company's R&D and commercialization investments. Future equity quality will depend heavily on the company's ability to transition from these deep losses to sustainable profitability.

PROF — Frequently Asked Questions

Quick answers to the most common questions about buying PROF stock.

What are the total assets of Profound Medical Corp. (PROF)?

As of 2025, Profound Medical Corp. (PROF) had total assets of $192.9M including $104.2M in current assets.

How much debt does Profound Medical Corp. (PROF) have?

Profound Medical Corp. (PROF) carries total debt of $6.5M, offset by $81.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Profound Medical Corp.?

Profound Medical Corp. (PROF) has total shareholders' equity (book value) of $91.0M ($3.01 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Profound Medical Corp.'s current ratio and liquidity?

Profound Medical Corp. (PROF) reported a current ratio of 12.52x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.